Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ajh.24074 http://scihub22266oqcxt.onion/10.1002/ajh.24074 C4546505!4546505!26017166     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Hematol 2015 ; 90 (9): 769-73 Nephropedia Template TP {{tp|p=26017166|t=2015. Bone marrow necrosis in acute leukemia: clinical characteristic and outcome |pdf=|usr=}}{{26017166}} gab.com Text Bone marrow necrosis in acute leukemia: clinical characteristic and outcome JO: Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=26017166 #FOAvip Background: Bone marrow necrosis (BMN) is characterized by infarction of the medullary stroma, leading to marrow necrosis with preserved cortical bone. In reported small series, BMN in hematological malignancies is associated with poor prognosis. We sought to find the impact of BMN on clinical outcome in a relatively larger cohort of patients with acute leukemias. Methods: Overall we evaluated 1691 patients; 1051 with acute myeloid leukemia (AML) and 640 with acute lymphocytic leukemia referred to our institution between 2002 and 2013. Patients with AML and ALL were evaluated separately to determine the incidence of BMN, associated clinical features and its prognostic significance. Results: At initial diagnosis; BMN was observed in 25 (2.4%) patients with AML and 20 (3.2%) patients with ALL. In AML, BMN was significantly associated with FAB AML M5 morphology (32% vs 10%, p = 0.002). The complete remission (CR) rate in AML with and without BMN was 32% and 59% respectively (p = 0.008). Likewise, CR rate in ALL with BMN was also inferior; 70% vs 92% (p = 0.005). The median overall survival (OS) in AML with BMN was significantly poorer; 3.7 months compared to 14 months without BMN (p= 0.003). Similarly, the median OS in ALL with and without BMN was 61.7 and 72 months respectively (p = 0.33). Conclusion: BMN is not a rare entity in AML and ALL, but is infrequent. BMN in AML and in ALL is suggestive of inferior response and poor prognosis. Twit Text FOAVip Bone marrow necrosis in acute leukemia: clinical characteristic and outcome ????Am J Hematol http://www.kidney.de/pget.php?&tw=1&pmid=26017166 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26017166 #FOAvip English Wikipedia <ref>{{Cite pmid|26017166}}</ref> Bone marrow necrosis in acute leukemia: clinical characteristic and outcome #MMPMID26017166 Badar T; Shetty A; Bueso-Ramos C; Cortes J; Konopleva M; Borthakur G; Pierce S; Huang X; Chen HC; Kadia T; Daver N; Dinardo C; O?Brien S; Garcia-Manero G; Kantarjian H; Ravandi F Am J Hematol 2015[Sep]; 90 (9): 769-73 PMID26017166show ga Background: Bone marrow necrosis (BMN) is characterized by infarction of the medullary stroma, leading to marrow necrosis with preserved cortical bone. In reported small series, BMN in hematological malignancies is associated with poor prognosis. We sought to find the impact of BMN on clinical outcome in a relatively larger cohort of patients with acute leukemias. Methods: Overall we evaluated 1691 patients; 1051 with acute myeloid leukemia (AML) and 640 with acute lymphocytic leukemia referred to our institution between 2002 and 2013. Patients with AML and ALL were evaluated separately to determine the incidence of BMN, associated clinical features and its prognostic significance. Results: At initial diagnosis; BMN was observed in 25 (2.4%) patients with AML and 20 (3.2%) patients with ALL. In AML, BMN was significantly associated with FAB AML M5 morphology (32% vs 10%, p = 0.002). The complete remission (CR) rate in AML with and without BMN was 32% and 59% respectively (p = 0.008). Likewise, CR rate in ALL with BMN was also inferior; 70% vs 92% (p = 0.005). The median overall survival (OS) in AML with BMN was significantly poorer; 3.7 months compared to 14 months without BMN (p= 0.003). Similarly, the median OS in ALL with and without BMN was 61.7 and 72 months respectively (p = 0.33). Conclusion: BMN is not a rare entity in AML and ALL, but is infrequent. BMN in AML and in ALL is suggestive of inferior response and poor prognosis. äBone marrow necrosis in acute leukemia: clinical characteristic and ou(epmc).pdf DeepDyve Pubget Overpricing